Engineered viruses that don’t replicate provide a tractable model for scientists to safely study SARS-CoV-2, including research into vaccine efficacy and emerging variants.

Facing new variants of SARS-CoV-2, some vaccines may offer more robust protection or be more easily redesigned to target them.

With many millions of people waiting several weeks to receive a second COVID-19 vaccine dose in some countries, experts consider the possibility that SARS-CoV-2 could evolve vaccine resistance.

Manipulating the production of new neurons can improve cognition in animal models of the disease, raising the possibility that figuring out a way for humans to make more neurons could make a difference for people with dementia.

Scientists across the world are closely tracking the spread of mutations in the coronavirus and investigating whether they could render current vaccines less effective.

As politicians try to schedule an end to the pandemic, scientists say the virus will stick around as an endemic disease similar to the common cold.

Autopsy studies have yet to find clear evidence of destructive viral invasion into patients’ brains, pushing researchers to consider alternative explanations of how SARS-CoV-2 causes neurological symptoms.

The third FDA approval of an RNAi-based therapeutic marks the growing success of a technique that took two decades to get off the ground.

Some researchers have turned their focus to artificial intelligence to study an underused symptom common to most respiratory pathogens—cough.